Full text
Earnings transcript
Read the complete earnings call transcript.
SUPN
Supernus Pharmaceuticals, Inc.
$45.66
1.18
(2.65%)
| Exchange: | NASDAQ |
| Market Cap: | 2.65B |
| Shares Outstanding: | 13.855M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – Specialty & Generic | |||||
| CEO: | Jack A. Khattar | |||||
| Full Time Employees: | 674 | |||||
| Address: |
| |||||
| Website: | https://www.supernus.com |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson’s Disease (PD) patients, APOKYN offers acute, intermittent relief during “off” episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson’s disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 607,521 | 661,817 | 718,952 |
| Gross Profit | 523,742 | 583,911 | 644,390 |
| EBITDA | 90,043 | 178,284 | 42,533 |
| Operating Income | -5,269 | 81,666 | -36,864 |
| Net Income | 1,316 | 73,865 | -38,550 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,277,673 | 1,368,073 | 1,452,648,000 |
| Total Liabilities | 356,157 | 332,340 | 390,934,000 |
| Total Stockholders Equity | 921,516 | 1,035,733 | 1,061,714,000 |
| Total Debt | 41,527 | 34,271 | 30,365,000 |
| Cash and Cash Equivalents | 75,054 | 69,331 | 128,448,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 111,085 | 171,951 | 47,331 |
| Capital Expenditure | -551 | -725 | -1,338 |
| Free Cash Flow | 110,534 | 171,226 | 45,993 |
| Net Income | 1,316 | 73,865 | -38,550 |
| Net Change in Cash | -18,066 | -5,723 | 60,567 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,339,329.618 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,379,312.753 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,360,595 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 248,962.410 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 256,394.709 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 252,915.344 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 381,322.349 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 396,191.579 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 389,230.589 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 757,363.819 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 779,973.473 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 769,388.962 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 6.900 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 7.020 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 6.750 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates SUPN intrinsic value between $44.20 – $45.02 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about SUPN valuation
Is Supernus Pharmaceuticals, Inc. (SUPN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Supernus Pharmaceuticals, Inc. (SUPN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SUPN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SUPN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SUPN’s P/E ratio?
You can see SUPN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SUPN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SUPN a good long-term investment?
Whether SUPN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SUPN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.65
Trading Metrics:
| Open: | 44.86 | Previous Close: | 44.48 | |
| Day Low: | 44.7 | Day High: | 45.79 | |
| Year Low: | 30.83 | Year High: | 59.68 | |
| Price Avg 50: | 49.06 | Price Avg 200: | 49 | |
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
